In this issue:
Nivolumab vs. docetaxel in advanced nonsquamous NSCLC
Pembrolizumab vs. docetaxel for progressive NSCLC
Pembrolizumab vs. chemotherapy for PD-L1- positive NSCLC
Carboplatin/pemetrexed ±pembrolizumab for advanced nonsquamous NSCLC
PD-1 blockade in tumours with MMR deficiency
Nivolumab for recurrent squamous-cell head and neck carcinoma
Pembrolizumab for platinumand cetuximab-refractory head and neck cancer
Nivolumab vs. everolimus in advanced renal-cell carcinoma
Nivolumab + ipilimumab in metastatic renal cell carcinoma
Atezolizumab in metastatic renal cell carcinoma
Please login below to download this issue (PDF)